Altimmune Stock Performance
| ALT Stock | USD 6.89 0.15 2.13% |
The firm shows a Beta (market volatility) of 3.78, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Altimmune will likely underperform. Altimmune has an expected return of -0.35%. Please make sure to confirm Altimmune treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Altimmune performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Altimmune has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in May 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (2.13) | Five Day Return (17.29) | Year To Date Return (34.51) | Ten Year Return (94.83) | All Time Return (94.83) |
Last Split Factor 1:30 | Dividend Date 2018-09-14 | Ex Dividend Date 2017-01-20 | Last Split Date 2018-09-14 |
1 | Altimmune Coverage Initiated at The Goldman Sachs Group - MarketBeat | 01/24/2024 |
2 | Stocks Start Week On A Hesitant Note | 02/26/2024 |
3 | Altimmune Trading 6.3 percent Higher - MarketBeat | 03/12/2024 |
4 | Heres How Much 100 Invested In Altimmune 5 Years Ago Would Be Worth Today | 03/18/2024 |
5 | Acquisition by Roberts M Scot of 1436 shares of Altimmune at 10.2085 subject to Rule 16b-3 | 03/22/2024 |
6 | Altimmune Inc Reports Q4 and Full Year 2023 Financial Results, Highlighting Pemvidutides ... | 03/27/2024 |
7 | Altimmune, Inc. Q4 2023 Earnings Call Transcript | 03/28/2024 |
8 | H.C. Wainwright lowers Altimmune stock PT, cites HepTcell program halt | 04/02/2024 |
9 | Temas Resources Completes First Tranche of Private Placement | 04/08/2024 |
10 | Altimmune, Inc. Shares Sold by SG Americas Securities LLC - Defense World | 04/11/2024 |
11 | Philippines Telecoms Industry Report 2024-2031, Featuring ABS-CBN, ALT Global Solutions, Bayantel, Converge ICT, Edgepoint, edotco, Globe Telecom, Lopez, Miesco... | 04/17/2024 |
| Begin Period Cash Flow | 111.1 M | |
| Free Cash Flow | -76.1 M |
Altimmune |
Altimmune Relative Risk vs. Return Landscape
If you would invest 1,004 in Altimmune on January 20, 2024 and sell it today you would lose (315.00) from holding Altimmune or give up 31.37% of portfolio value over 90 days. Altimmune is generating negative expected returns assuming volatility of 7.1477% on return distribution over 90 days investment horizon. In other words, 63% of stocks are less volatile than Altimmune, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Altimmune Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Altimmune's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Altimmune, and traders can use it to determine the average amount a Altimmune's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0493
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALT |
Estimated Market Risk
| 7.15 actual daily | 63 63% of assets are less volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Altimmune is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Altimmune by adding Altimmune to a well-diversified portfolio.
Altimmune Fundamentals Growth
Altimmune Stock prices reflect investors' perceptions of the future prospects and financial health of Altimmune, and Altimmune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Altimmune Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (573.08) % | ||||
| Current Valuation | 301.96 M | ||||
| Shares Outstanding | 70.9 M | ||||
| Price To Earning | (1.66) X | ||||
| Price To Book | 2.92 X | ||||
| Price To Sales | 1,330 X | ||||
| Revenue | 426 K | ||||
| Gross Profit | (70.52 M) | ||||
| EBITDA | (83.03 M) | ||||
| Net Income | (88.45 M) | ||||
| Cash And Equivalents | 184.76 M | ||||
| Cash Per Share | 3.81 X | ||||
| Total Debt | 671 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.12 X | ||||
| Book Value Per Share | 2.75 X | ||||
| Cash Flow From Operations | (76 M) | ||||
| Earnings Per Share | (1.66) X | ||||
| Market Capitalization | 488.47 M | ||||
| Total Asset | 210.64 M | ||||
| Retained Earnings | (466.33 M) | ||||
| Working Capital | 197.48 M | ||||
| Current Asset | 13.9 M | ||||
| Current Liabilities | 10.49 M | ||||
About Altimmune Performance
To evaluate Altimmune Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Altimmune generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Altimmune Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Altimmune market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Altimmune's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 209.87 | 220.37 | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.46) | (0.48) |
Things to note about Altimmune performance evaluation
Checking the ongoing alerts about Altimmune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Altimmune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Altimmune generated a negative expected return over the last 90 days | |
| Altimmune has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 426 K. Reported Net Loss for the year was (88.45 M) with loss before taxes, overhead, and interest of (70.52 M). | |
| Altimmune has about 184.76 M in cash with (76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81. | |
| Altimmune has a poor financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Philippines Telecoms Industry Report 2024-2031, Featuring ABS-CBN, ALT Global Solutions, Bayantel, Converge ICT, Edgepoint, edotco, Globe Telecom, Lopez, Miescor, Mislatel, Radius Telecom and More - ResearchAndMarkets.com |
- Analyzing Altimmune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Altimmune's stock is overvalued or undervalued compared to its peers.
- Examining Altimmune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Altimmune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Altimmune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Altimmune's stock. These opinions can provide insight into Altimmune's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Altimmune Stock analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Revenue Per Share 0.008 | Quarterly Revenue Growth 180 | Return On Assets (0.25) | Return On Equity (0.47) |
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.